Physician profile
Donald K Marcus
NPI 1003880071
$3,988.47
in general payments reported to CMS, 2019-2025
24 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $634 · 2021: $283 · 2022: $511 · 2023: $637 · 2024: $560 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612 · Education: $64.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.35 |
| Education | $64.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $766.10 | 2019-2025 | Arikayce |
| Abbvie INC. | $469.72 | 2021-2025 | |
| Viiv Healthcare Company | $467.31 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Allergan, INC. | $415.40 | 2019-2020 | |
| Gilead Sciences, INC. | $378.17 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $293.30 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Janssen Biotech, INC. | $270.91 | 2019-2022 | |
| Melinta Therapeutics, LLC | $212.99 | 2019-2025 | Vabomere, Orbactiv, Kimyrsa |
| Cumberland Pharmaceuticals, INC. | $145.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $103.43 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $82.41 | 2019 | |
| Ferring Pharmaceuticals INC. | $68.36 | 2022-2025 | Rebyota |
| Paratek Pharmaceuticals, INC. | $52.58 | 2020-2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $51.81 | 2020-2023 | Cuvitru |
| Aimmune Therapeutics, INC. | $42.42 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.53 | 2024 | |
| Napo Pharmaceuticals INC | $23.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.04 | 2020 | |
| Vyera Pharmaceuticals, LLC | $19.88 | 2019 | |
| La Jolla Pharmaceutical Company | $16.24 | 2025 | Xacduro |
| Bio Products Laboratory USA, INC. | $14.43 | 2019 | |
| Theratechnologies INC. | $13.77 | 2019 | |
| Astellas Pharma US INC | $12.24 | 2021 | |
| Redhill Biopharma INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.